文献速递分子诊断临床微生物

Acuitas抗菌药物耐药基因检测板的多中心评估

Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates.
PubMed 文献 · J Clin Microbiol · 2022-03-16

Acuitas AMR基因检测板是一种定性多重核酸检测试剂,可检测与鉴定特定肠杆菌科、铜绿假单胞菌和粪肠球菌培养分离株中28种抗菌药物耐药标记。研究在四个中心对584株回顾性收集和83株前瞻性收集的临床分离株创建的1,224份去标识菌株库存进行检测,并与全基因组测序、菌种鉴定和表型药敏试验组合参考标准比较。FDA认证靶标的阳性符合率范围为94.4%(MCR-1)至100%(armA、CTX-M-2、DHA、IMP、OXA-9、SHV、vanA和VEB),多数靶标的阴性符合率≥99%。

要点

  • Acuitas AMR基因检测板可准确检测多种抗菌药物耐药标记。
  • FDA认证靶标的PPA为94.4%至100%,多数靶标NPA≥99%。
  • 检测到的耐药标记与特定药物-菌种组合的非敏感结果相关。

核心结论

  • Acuitas AMR基因检测板是检测培养分离株中广泛抗菌药物耐药标记的准确方法。
  • 耐药标记与特定药物-菌种组合的预期非敏感结果相关。

研究设计与样本

  • 研究在四个中心进行,检测了1,224份去标识菌株库存,来自584株回顾性收集和83株前瞻性收集的临床分离株。
  • 以全基因组测序、菌种鉴定和表型抗菌药物敏感性试验的组合作为参考标准。

主要发现

  • FDA认证靶标的阳性符合率范围为94.4%(MCR-1)至100%(armA、CTX-M-2、DHA、IMP、OXA-9、SHV、vanA和VEB)。
  • 多数靶标的阴性符合率≥99%,但AAC、AAD、CMY-41、铜绿假单胞菌gyrA突变体、Sul1、Sul2和TEM靶标例外(范围96.5%至98.5%)。
  • GES、SPM和MCR-2三个耐药标记未满足FDA纳入标准。
  • 对每种菌种,有1至22个耐药标记满足最低可报告阳性/阴性符合率,并与至少一种药物的非敏感结果具有≥80%的阳性预测值。

关键数值与推荐

  • FDA认证靶标的PPA范围为94.4%至100%,多数靶标NPA≥99%,例外靶标NPA范围为96.5%至98.5%。

临床怎么用

  • 该检测板可用于培养分离株中多种抗菌药物耐药标记的检测。
  • 检测结果可关联特定药物-菌种组合的非敏感结果。

局限性

  • GES、SPM和MCR-2三个耐药标记未满足FDA纳入标准。
  • 部分靶标(AAC、AAD、CMY-41、铜绿假单胞菌gyrA突变体、Sul1、Sul2和TEM)的NPA低于99%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Acuitas antimicrobial resistance (AMR) gene panel is a qualitative, multiplex, nucleic acid-based in vitro diagnostic test for the detection and differentiation of 28 antimicrobial resistance markers associated with not susceptible results (NS; i.e., intermediate or resistant) to one or more antimicrobial agents among cultured isolates of select Enterobacterales, Pseudomonas aeruginosa, and Enterococcus faecalis. This study was conducted at four sites and included testing of 1,224 deidentified stocks created from 584 retrospectively collected isolates and 83 prospectively collected clinical isolates. The Acuitas results were compared with a combined reference standard including whole-genome sequencing, organism identification, and phenotypic antimicrobial susceptibility testing. The positive percent agreement (PPA) for FDA-cleared AMR targets ranged from 94.4% for MCR-1 to 100% for armA, CTX-M-2, DHA, IMP, OXA-9, SHV, vanA, and VEB. The negative percent agreement (NPA) for the majority of targets was ≥99%, except for AAC, AAD, CMY-41, P. aeruginosa gyrA mutant, Sul1, Sul2, and TEM targets (range, 96.5% to 98.5%). Three AMR markers did not meet FDA inclusion criteria (GES, SPM, and MCR-2). For each organism, 1 to 22 AMR targets met the minimum reportable PPA/NPA and correlated with ≥80% positive predictive value with associated NS results for at least one agent (i.e., the probability of an organism carrying an AMR marker testing NS to the associated agent). We demonstrate that the Acuitas AMR gene panel is an accurate method to detect a broad array of AMR markers among cultured isolates. The AMR markers were further associated with expected NS results for specific agent-organism combinations.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Simner PJ, Musser KA, Mitchell K, et al. Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates. J Clin Microbiol. 2022. PMID: 35138924. doi:10.1128/JCM.02098-21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。